Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort

Journal of Diabetes and its Complications

Volumn 19, Issue 1, 2005, Pages 18-25

  Klein, Richard L ^a,b,c   McHenry, M Brent ^c   Lok, Kerry H ^d   Hunter, Steven J ^a   Le, Ngoc Anh ^e   Jenkins, Alicia J ^a,f,g   Zheng, Deyi ^c   Semler, Andrea ^a   Page, Grier ^d   Brown, W Virgil ^e   Lyons, Timothy J ^g   Garvey, W Timothy ^d,h  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

AER; albumin excretion rate; ApoCIII; apolipoprotein C III; DCCT EDIC; Diabetes Control and Complications Trial Epidemiology of Diabetes Intervention and Complications; Early Treatment Diabetic Retinopathy Study; ETDRS; untranslated region; UTR

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINURIA; SEX DIFFERENCE;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

EID: 19944425974     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2004.04.005     Document Type: Article

References (49)

1. Aalto-Setala K., Fisher E.A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., Walsh A., Ramakrishnan R., Ginsberg H.N., Breslow J.L. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. Journal of Clinical Investigation. 90:1992;1889-1900
2. Aalto-Setälä K., Kontula K., Sane T., Nieminen M., Nillila E. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis. 66:1987;145-152
3. Blankenhorn D.H., Alaupovic P., Wichham E., Chin H.P., Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 81:1990;470-476
4. Boyle K.E., Phillips M.C., Lund-Katz S. Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochimica et Biophysica Acta. 1430:1999;302-312
5. Breyer E.D., Le N.A., Li X., Martinson D., Brown W.V. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. Journal of Lipid Research. 40:1999;1875-1882
6. Chavers B.M., Simonson J., Michael A.F. A solid phase fluorescent immunoassay for the measurement of human urinary albumin. Kidney International. 25:1984;576-578
7. Chen M., Breslow J.L., Li W., Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. Journal of Lipid Research. 35:1994;1918-1924
8. Dallongeville J., Meirhaeghe A., Cottel D., Fruchart J.C., Amouyel P., Helbecque N. Gender associated association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Arteriosclerosis. 150:2000;149-157
9. Dammerman M., Sandkuijl L.A., Halaas J.L., Chung W., Breslow J.L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proceedings of the National Academy of Sciences, USA. 90:1993;4562-4566
10. DCCT Research Group The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes. 35:1986;530-545
11. DCCT Research Group. (1993). DCCT manual of operations (Publ. No. 93-183382). Springfield, VA: National Technical Information Service.
12. Deighan C.J., Caslake M.J., McConnell M., Boulton-Jones J.M., Packard C.J. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL 1. Kidney International. 58:2000;1238-1246
13. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report no. 12. Opthalmology. 98:1991;823-833
14. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic color fundus photographs - An extension of the modified Airlie House classification: ETDRS report no. 10. Opthalmology. 98:1991;786-806
15. Ebara T., Ramakrishnan R., Steiner G., Shachter N.S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E null mice: Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. Journal of Clinical Investigation. 99:1997;2672-2681
16. EDIC Research Group Epidemiology of diabetes interventions and complications (EDIC): design, implementation and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 22:1999;977-986
17. Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab. 24:1998;490-495
18. Gervaise N., Garrigue M.A., Lasfargues G., Lecomte P. Triglycerides, apo C3, and LpB:C3 and cardiovascular risk in Type II diabetes. Diabetologia. 43:2000;703-708
19. Groenendijk M., Cantor R.M., Bloom N.H.H.C., Rotter J.I., de Bruin T.W.A., Dallinga-Thie G.M. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. Journal of Lipid Research. 40:1999;1036-1044
20. Hedrick P.W. Gametic disequilibrium measures: proceed with caution. Genetics. 117:1987;331-341
21. Hegele R.A., Connelly P.W., Hanley A.J., Sun F., Harris S.B., Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology. 17:1997;2753-2758
22. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:1994;42-49
23. Hoffer M.J., Sijbrands E.J., De Man F.H., Havekes L.M., Smelt A.H., Frants R.R. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. European Journal of Clinical Investigation. 28:1998;807-812
24. Jong M.C., Hofker M.H., Havekes L.M. Role of apoCs in lipoprotein metabolism: functional differences between ApoC1, apoC2, and ApoC3. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;472-484
25. Klein, R. L., Brent, M. M., Hunter, S. J., Le, N.-A., Jenkins, A. J., Zheng, D., Semler, A. J., Page, G., Brown, W. V., Lyons, T. J., Garvery, W. T., & the DCCT/EDIC Research Group. (in press). Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with lipoprotein subclasses. Metabolism.
26. Koren E., Corder C., Mueller G., Centurion H., Hallum G., Fesmire J., et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 122:1996;105-115
27. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Current Opinion in Lipidology. 5:1994;339-349
28. Lamarche B., Moojani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Despres J.P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 94:1996;273-278
29. Le N.-A., Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D., Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reduction with atorvastatin. Metabolism. 49:2000;167-177
30. Lee S.-J., Campos H., Moye L.A., Sacks F.M. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 23:2003;853-858
31. Li W.W., Dammennan M.M., Smith J.D., Metzger S., Breslow J.L., Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. Journal of Clinical Investigation. 96:1995;2601-2605
32. Luc C., Fievet C., Arveiler D., Evans A.E., Bard J.-M., Cambien F., et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Journal of Lipid Research. 37:1996;508-517
33. Maeda N., Li H., Lee D., Oliver P., Quarfordt S.H., Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. Journal of Biological Chemistry. 269:1994;23610-23616
34. McConathy J., Gesquiere J.C., Bass H., Tartar A., Fruchart J.C., Wang C.-S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. Journal of Lipid Research. 33:1992;995-1003
35. Ordovas J.M., Civeira F., Genest J. Jr., Craig S., Robbins A.H., Meade T., et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 87:1991;75-86
36. Ordovas J.M., Schaefer E.J., Salem D., Ward R.H., Glueck C.J., Vergani C., et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. New England Journal of Medicine. 314:1986;671-677
37. Peacock R.E., Temple A., Gudnason V., Rossenue M., Humphries S.E. Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Genetic Epidemiology. 14:1997;265-282
38. Renard E., Dupuy A.M., Momtier L., Crastes de Paulet A. DNA restriction polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster: a genetic determinant of atherosclerosis in type 2 (non-insulin-dependent) diabetes mellitus. Diabetic Medicine. 8:1991;354-360
39. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation. 102:2000;1886-1892
40. Schonfeld G., George P.K., Miller J., Reilly P., Witzum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28:1979;1001-1010
41. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Current Opinion in Lipidology. 12:2001;297-304
42. Shoulders C.C., Grantham T.T., North J.D., Gaspardone A., Tomai F., De Fazio A., et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Human Genetics. 98:1996;557-566
43. Stocks J., Paul H., Galton D.J. Haplotypes identified by DNA restriction-fragment-length polymorphisms in A-I/C-III/A-IV gene region and hypertriglyceridemia. American Journal of Human Genetics. 41:1987;106-118
44. Surguchov A.P., Page G.P., Smith L., Patsch W., Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 16:1996;941-947
45. Talmud P.J., Humphries S.E. Apolipoprotein C-III gene variation and dyslipidemia. Current Opinion in Lipidology. 8:1997;154-158
46. Terwilliger J.D., Ott J. Handbook of genetic linkage. 1994;Johns Hopkins Press, Baltimore, MD
47. Wang C.-S., McConathy J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein CIII. Journal of Clinical Investigation. 75:1985;384-390
48. Wijsman E.M., Brunzell J.D., Jarvik G.P., Austin M.A., Motulsky A.G., Deeb S.S. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arteriosclerosis, Thrombosis, and Vascular Biology. 18:1998;215-226
49. Wile D.B., Barbir M., Gallagher J., Myant N.B., Ritchie C.D., Thompson G.R. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration. Atherosclerosis. 78:1989;9-18